Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic Peptides
Summary
Macrocycles are a natural and uniquely efficacious modality, and, powered by Insamos AI-driven engineering, they can create safer and more potent oral therapeutics. Insamos technology unlocks the potential to engineer macrocycles with improved properties and develop new therapies for previously undruggable targets across a broad range of diseases with high unmet need. This innovative platform truly discovers membrane-permeable cyclic-peptides with oral bioavailability and binding capabilities akin to monoclonal antibodies," said Dr. Corey Goodman, co-founder of venBio. "The companys capacity to synthesize and screen libraries containing trillions of molecules facilitates the discovery of high-affinity ligands for drug targets across a spectrum of diseases. The MRLV team of experienced-life sciences venture capital professionals is committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease.